Literature DB >> 20206498

Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.

Marjo Pylväs1, Ulla Puistola, Saila Kauppila, Ylermi Soini, Peeter Karihtala.   

Abstract

Oxidative stress and antioxidant enzymes have been widely investigated in various carcinomas. However, there is only some information about their role in ovarian carcinogenesis or in ovarian carcinomas in vivo. We studied immunohistochemical nuclear and/or cytoplasmic expression of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine, as well as major antioxidative enzymes peroxiredoxins (PRDX) I-VI and thioredoxin (TXN) in ovarian tumours. The material consisted of 20 benign (10 serous, 10 mucinous) and 51 borderline (33 serous, 18 mucinous) epithelial ovarian tumours. The markers of oxidative stress, 8-OHdG and nitrotyrosine, were seen already in benign tumours (in 20% and 45% of the tumours, respectively) and their expression patterns were similar in benign and borderline tumours. The levels of PRDX II, III, IV, V and VI were significantly higher in borderline than in benign tumours (p<0.02 for all). Specifically for PRDX II (for both nuclear and cytoplasmic expression, p<0.00005) and PRDX VI (for cytoplasmic expression, p=0.0003 and for nuclear expression, p=0.0005) the difference between benign and borderline tumours was remarkable. In general, serous benign and borderline tumours expressed higher antioxidant enzyme levels than mucinous ones. Nuclear TXN was expressed more strongly in benign than in borderline tumours (p=0.003). Oxidative stress occurs already in benign ovarian tumours and the levels are comparable to borderline tumours. However, some of the antioxidant enzymes, especially PRDX II and VI, are more profoundly induced in borderline ovarian tumours, reflecting their possible role as cancer preventers. This difference could also offer a potential tool for differential diagnosis between benign and borderline epithelial ovarian tumours. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206498     DOI: 10.1016/j.ejca.2010.02.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

2.  8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Authors:  Ylermi Soini; Kirsi-Maria Haapasaari; Markku H Vaarala; Taina Turpeenniemi-Hujanen; V Kärjä; Peeter Karihtala
Journal:  Int J Clin Exp Pathol       Date:  2011-03-02

3.  Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.

Authors:  Jie Zhou; Weiwen Shen; Xiaojing He; Jing Qian; Shiyuan Liu; Guanzhen Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  The critical role of peroxiredoxin-2 in colon cancer stem cells.

Authors:  Linglong Peng; Yongfu Xiong; Rong Wang; Ling Xiang; He Zhou; Zhongxue Fu
Journal:  Aging (Albany NY)       Date:  2021-03-26       Impact factor: 5.682

5.  Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation.

Authors:  Ebony R Hoskins; Brian L Hood; Mai Sun; Thomas C Krivak; Robert P Edwards; Thomas P Conrads
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

6.  Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration.

Authors:  Janin Schulte
Journal:  BMC Med       Date:  2011-12-23       Impact factor: 8.775

7.  Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.

Authors:  Marjo Pylväs-Eerola; Peeter Karihtala; Ulla Puistola
Journal:  BMC Cancer       Date:  2015-07-02       Impact factor: 4.430

8.  Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress.

Authors:  H C Whitaker; D Patel; W J Howat; A Y Warren; J D Kay; T Sangan; J C Marioni; J Mitchell; S Aldridge; H J Luxton; C Massie; A G Lynch; D E Neal
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

9.  Integrative analysis the characterization of peroxiredoxins in pan-cancer.

Authors:  Lei Gao; Jialin Meng; Chuang Yue; Xingyu Wu; Quanxin Su; Hao Wu; Ze Zhang; Qinzhou Yu; Shenglin Gao; Song Fan; Li Zuo
Journal:  Cancer Cell Int       Date:  2021-07-10       Impact factor: 5.722

10.  Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.

Authors:  Outi Kuittinen; Peeter Karihtala; Pekka Peroja; Anna Kaisa Pasanen; Kirsi-Maria Haapasaari; Esa Jantunen; Ylermi Soini; Taina Turpeenniemi-Hujanen; Risto Bloigu; Laura Lilja
Journal:  Exp Hematol Oncol       Date:  2012-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.